- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NICE Prevents Use of Zytiga Prior to Chemotherapy
Britain's healthcare cost-effectiveness agency, NICE, has recommended against using Zytiga in chemotherapy-naive prostate cancer patients.
Britain's healthcare cost-effectiveness agency NICE said on Wednesday that a prostate cancer drug, originally invented in Britain, was not worth giving to patients who have yet to receive chemotherapy.
Although Zytiga, or abiraterone, is already cleared for use in some men after chemotherapy, a green light for its earlier use would allow many more patients to access the oral medicine.
"We know how important it is for patients to have the option to delay chemotherapy and its associated side effects, so we are disappointed not to be able to recommend abiraterone for use in this way," Andrew Dillon, chief executive of the National Institute for Health and Care Excellence (NICE), said in a statement.
Read the report here:
Source: Reuters
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
